Displaying drugs 14426 - 14450 of 15432 in total
3-ETHYL-2-(4-HYDROXYPHENYL)-2H-INDAZOL-5-OL
Experimental
Ethadione
Experimental
OSI-7904L
OSI-7904L is a liposome encapsulated thymidylate synthase inhibitor, which is indicated for use in advanced gastric and/or gastroesophageal adenocarcinoma (A-G/GEJA). Current treatments also inhibit thymidylate synthase but the innovative lipid coating of OSI-7904L allows for more enduring results with administration of the TS inhibitor.
Investigational
Matched Description: … liposome encapsulated thymidylate synthase inhibitor, which is indicated for use in advanced gastric and …
SO-101
SO-101(Silenor) is a low-dose oral tablet formulation of doxepin hydrochloride that is patent protected for its use in insomnia. Doxepin has been prescribed for more than 40 years for the treatment of depression and anxiety at dosages typically ranging from 75 mg to 300 mg per day.
Investigational
Matched Description: … Doxepin has been prescribed for more than 40 years for the treatment of depression and anxiety at dosages …
Reproxalap
Reproxalap (previously ADX 102 or NS-2) is a small molecule inhibitor being developed by Aldeyra Therapeutics investigated against dry eye disease, allergic conjunctivitis, noninfectious anterior uveitis, and Sjögren-Larsson syndrome. NS-2 has orphan drug status due to it being investigated for treatment of Sjogren-Larsson syndrome.
Investigational
Matched Description: … Therapeutics investigated against dry eye disease, allergic conjunctivitis, noninfectious anterior uveitis, and …
Giloralimab
Giloralimab is under investigation in clinical trial NCT04807972 (Study to Evaluate Adverse Events and Change in Disease Activity When Intravenous (IV) Infusion of ABBV-927 Is Administered in Combination With IV Modified FOLFIRINOX (Mffx) With or Without IV Budigalimab Compared to Mffx in Adult Participants With Untreated Pancreatic Cancer Metastasis).
Investigational
Matched Description: … Giloralimab is under investigation in clinical trial NCT04807972 (Study to Evaluate Adverse Events and …
EHT899
EHT899 is a proprietary formulation of an HBV viral protein designed to eliminate the undesirable immune response elicited by the HBV infection. It also apparently enhances a secondary immune response to clear the viral infection, resulting in reduction in liver damage and decrease in viral load.
Investigational
Matched Description: … enhances a secondary immune response to clear the viral infection, resulting in reduction in liver damage and …
RUS 3108
RUS 3108 is being developed for the treatment of atherosclerosis, the major cause of cardiovascular disorders such as heart attacks and stroke by Dr. Reddy’s Laboratories.
The drug’s Phase I clinical trials have been initiated in Europe to assess safety of the drug compound in healthy volunteers.
Investigational
Matched Description: … the treatment of atherosclerosis, the major cause of cardiovascular disorders such as heart attacks and …
3-hydroxyisoxazole-4-carboxylic acid
Experimental
4-Sulfonamide-[1-(4-Aminobutane)]Benzamide
Experimental
Cambendazole
Experimental
Vet approved
(C8-S)-Hydantocidin 5'-phosphate
Experimental
Matched Iupac: … (2S)-5-[(5S,7R,8S,9R)-8,9-dihydroxy-2,4-dioxo-7-[(phosphonooxy)methyl]-6-oxa-1,3-diazaspiro[4.4]nonan …
Zotatifin
Zotatifin is under investigation in clinical trial NCT04092673 (Study of Eft226 in Subjects With Selected Advanced Solid Tumor Malignancies).
Investigational
Matched Iupac: … 4-[(2S,3R,4S,5S,6R)-4-[(dimethylamino)methyl]-2,3-dihydroxy-10,12-dimethoxy-5-phenyl-7-oxa-11-azatricyclo …
3h-Indole-5,6-Diol
Experimental
Xylose-derived lactam oxime
Experimental
D-gluconhydroximo-1,5-lactam
Experimental
Hydrogenobyrinic acid
Experimental
Indirubin-5-sulphonate
Experimental
Siroheme
Experimental
2-Acetyl-Protoporphyrin Ix
Experimental
IC261
Experimental
Displaying drugs 14426 - 14450 of 15432 in total